Comments
Strides Pharma Science Ltd has announced that its step‐down wholly-owned subsidiary, Strides Pharma Global Pte Ltd, Singapore, has received approval for Gabapentin Tablets USP, 600 mg and 800 mg, from the United States Food & Drug Administration (USFDA).
The tablets will be manufactured at the company’s facility in Puducherry.
The product is equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty LLC, Strides Pharma has said in its stock exchange filing.
Strides Pharma Science stock surged by 3.46 per cent on the NSE, trading at ₹824.05 as of 1:19 pm.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.